Millipore Strengthens Position in Virus Safety with Launch of Innovative Product Line

Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market. Millipore made the announcement at the 28^th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

"Virus safety is an increasingly critical issue in the biopharmaceutical industry and recent incidents of viral contamination have highlighted why effective virus safety solutions are so important for our customers,” said Jean-Paul Mangeolle, President of Millipore’s Bioprocess Division. "The launch of Viresolve Pro+ Solution expands our industry-leading virus safety offerings, which help companies address increasingly diverse and difficult virus-removal challenges, improve the productivity of their manufacturing processes, and ensure the safety and quality of their products.”

Biological drug products such as monoclonal antibodies and therapeutic proteins are manufactured using biological source material and production processes that can become contaminated with viruses. As a result, biopharmaceutical manufacturers are required to incorporate sufficient virus clearance steps into their manufacturing processes to ensure their products are free of virus contamination.

Millipore’s virus safety products provide customers with effective and robust virus filtration, from process development to full-scale biopharmaceutical production. Viresolve Pro+ Solution strengthens Millipore’s offerings by providing a robust parvovirus clearance that works effectively at higher titer feedstreams. Parvoviruses are some of the smallest viruses found in nature, which makes them particularly difficult to remove in the manufacturing process.

Viresolve Pro+ Solution is available in a disposable flow path and increases the overall capacity and productivity of biopharmaceutical manufacturers’ virus removal operations. It is designed to fit both monoclonal antibody and therapeutic protein processes. It also includes a proprietary binary gas integrity test (BGT) to detect the presence of oversized pores or defects that can compromise a filter’s retention capability and cause contamination in the end product—providing a critical quality-control safeguard for the end user.

"As we continue to launch more innovative virus products, we’re leveraging our product breadth and applications expertise to offer customers complete virus safety solutions,” noted Paul Chapman, Millipore’s Vice President, Downstream Processing. "Later this year we’ll introduce additional validation services and turn-key solutions to help our customers address their complex virus safety challenges.”

About Millipore:

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER ®

Research. Development. Production.

Forward Looking Statements:

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug; delay, suspension or termination of a customer’s volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of customers’ therapeutics; limitations on cash flow available for operations and investment due to increased debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for animal-derived cell culture products; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; the inability to achieve anticipated cost benefits of our supply chain initiatives; risks relating to our concentration of principal manufacturing operations; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Millipore, Viresolve and ADVANCING LIFE SCIENCE TOGETHER are registered trademarks; the "M” logo is a trademark of Millipore Corporation.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6136671&lang=en